Effect of Long-lasting Adaptation to Endurance and Speed-power Training on Plasma Free Amino Acids Concentration
NCT ID: NCT05672758
Last Updated: 2023-01-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
58 participants
Study Classification
OBSERVATIONAL
Study Start Date
2018-07-31
Study Completion Date
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this observational study was to detect the long-term effect of two different training modalities - speed-power and endurance training - on changes in plasma free amino acid (PFAA) concentration at rest, during graded exercise and post-exercise recovery period. It was assumed that these training modalities cause different amino acids concentration in human blood depending on long-term sport specialization and predominant exercise type (the contribution of high-intensity exercise related to anaerobic metabolism). The hypotheses were:
1. highly-trained speed-power have higher concentrations of PFAA than endurance athletes;
2. PFAA concentration varies with the change in training loads in a one-year training cycle. Higher PFAA concentrations is expected in training phases with larger contribution of high-intensity exercise;
3. PFAA concentration per 1 kg muscle mass differ between speed-power and endurance athletes.
Forty-eght highly-trained athletes aged 18-32 years with longer competitive sport experience - sprinters vs triathletes/distance runners - and 10 recreationally trained controls were examined. Laboratory tests were conducted in consecutive training subphases.
(i) Body composition and muscle mass was assessed using densitometry. (ii) Participants underwent a graded exercise treadmill test until exhaustion. (iii) Blood samples were drawn at rest, during exercise (every 3 min, at each speed change), and after exercise (immediately and 5, 10, 15, 20 and 30 min post exercise).
(iv)The analysis of PFAA profiles was based on the Liquid Chromatography Electrospray Ionization tandem Mass Spectrometry (LC-ESI-MS/MS) technique and the aTRAQ reagent. This allowed to quantify 42 PFAAs.
The results improve the understanding of metabolic adaptation to long-term exercise programmes. Possible practical application encompasses the domains of exercise medicine, sport and public health.
The novelty of the project: (1) comparing the effect of two different training models on PFAA concentration, (2) tracking the changes in PFAAs across a one-year training cycle, (3) repeated multiple sampling in one exercise session including resting conditions, (4) introducing skeletal muscle mass as a factor potentially affecting PFAA profiles, (5) a large number (42) of proteinogenic- and non-proteinogenic PFAAs, (6) homogenous highly-trained athletic groups, and (7) a proven state-of-the-art method to determine PFAAs.
1. highly-trained speed-power have higher concentrations of PFAA than endurance athletes;
2. PFAA concentration varies with the change in training loads in a one-year training cycle. Higher PFAA concentrations is expected in training phases with larger contribution of high-intensity exercise;
3. PFAA concentration per 1 kg muscle mass differ between speed-power and endurance athletes.
Forty-eght highly-trained athletes aged 18-32 years with longer competitive sport experience - sprinters vs triathletes/distance runners - and 10 recreationally trained controls were examined. Laboratory tests were conducted in consecutive training subphases.
(i) Body composition and muscle mass was assessed using densitometry. (ii) Participants underwent a graded exercise treadmill test until exhaustion. (iii) Blood samples were drawn at rest, during exercise (every 3 min, at each speed change), and after exercise (immediately and 5, 10, 15, 20 and 30 min post exercise).
(iv)The analysis of PFAA profiles was based on the Liquid Chromatography Electrospray Ionization tandem Mass Spectrometry (LC-ESI-MS/MS) technique and the aTRAQ reagent. This allowed to quantify 42 PFAAs.
The results improve the understanding of metabolic adaptation to long-term exercise programmes. Possible practical application encompasses the domains of exercise medicine, sport and public health.
The novelty of the project: (1) comparing the effect of two different training models on PFAA concentration, (2) tracking the changes in PFAAs across a one-year training cycle, (3) repeated multiple sampling in one exercise session including resting conditions, (4) introducing skeletal muscle mass as a factor potentially affecting PFAA profiles, (5) a large number (42) of proteinogenic- and non-proteinogenic PFAAs, (6) homogenous highly-trained athletic groups, and (7) a proven state-of-the-art method to determine PFAAs.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post-activation Potentiation and Sprinting Performance
NCT06619899
Sprint Performance
COMPLETED
NA
Recovery of Performance, Muscle Damage and Neuromuscular Fatigue Following Muscle Power Training
NCT03936595
Power Training Exercise Protocols
TERMINATED
NA
Effects of Including Sprints During Low-intensity Cycling Exercises on Performance and Muscle/Blood Characteristics
NCT04640883
Healthy
Cyclists
COMPLETED
NA
Strength Training for Injury Prevention
NCT02927418
Wounds and Injuries
COMPLETED
NA
Recovery Kinetics Following a Soccer Training in Middle-aged Males
NCT06260215
Skeletal Muscle Damage
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Study goal
Long-term effect of two different training modalities - speed-power and endurance training - on changes in plasma free amino acid (PFAA) concentration at rest, during graded exercise until exhaustion and recovery period was compared. The model cohorts were highly-trained athletes. The assumption was that structured long-lasting speed-power and endurance training cause adaptations resulting in different PFAA concentration and that the changes depend on long-term sport specialization (predominant exercise type) and training phase of the one-year cycle (contribution of high-intensity exercise based on anaerobic metabolism characterized by rapid adenosine-5'-triphosphate degradation). A larger contribution of high-intensity exercise is used by speed-power athletes and in phases of specific preparation/competition. There is a lack of research on long-term effects of physical training on changes in PFAAs. This picture is supllemented by monitoring changes in a set of 42 proteinogenic and non-proteinogenic PFAAs. Short- and long-lasting effects of training on levels and time course of PFAA concentration during exercise and recovery will be shown. The main goals were:
1. To compare the effect of the two entirely different training modalities (speed-power and endurance) on PFAA concentration.
2. To observe the effect of training load character on changes in resting, exercise and post-exercise PFAA concentration in consecutive training phases of a one-year training cycle.
3. To determine the link between PFAA concentration and exercise modality, taking into account skeletal muscle mass.
II. Background
Only 3-6% of the total energy utilized during prolonged endurance exercise is derived from oxidation of AAs. However, the proportion of energy from AA catabolism considerably increases during exercise. Although protein turnover does not contribute substantially to the energy expenditure, it may fill other important functions during exercise. AAs may delay muscle glycogen depletion.
The free AA pool amounts only 2% of the total AA amount and is stored within the plasma and intra- and extracellular spaces. This small pool accounts for a continuous exchange of AAs. Blood plasma serves as a temporary reservoir of AAs, the size of which changes in response to exercise. Differences in regular training, exercise, and daily activities result in differences in PFAA levels.
Exercise duration affects PFAA levels, however, the direction of the changes may be different for specific AAs and exercise type, intensity, and duration. In contrast, muscle AAs concentration remains relatively stable. AA metabolism during prolonged exercise has been described. Reports based on a short training periods (few weeks) in power-type athletes suggest that sprint and endurance training sessions have a distinct effect on serum AAs. However, there is a lack of studies on the differences in long-term adaptation changes in PFAAs between endurance- and sprint-trained individuals, taking into account multiple blood sampling (rest, exercise, recovery) and muscle mass.
III. Methods
Over 70 athletes aged 18-32 years - speed-power (sprinters), endurance (triathletes, distance runners), and recreationally trained - were recruited. Eventually, the data of 58 of them were considered for analysis. Athletes were examined four times during one-year training cycle: (1) general preparation phase, (2) specific preparation phase, (3) competition phase, and (4) transition phase.
The main statistical tool was one-way and two-way ANOVA with repeated measures. The required sample size was computed based on given alpha (significance) level, statistical power, and effect size. The significance level α \< 0.05 and statistical power 0.8 were assumed. Based on earlier studies that compared sprint- and endurance-trained athletes in terms of other metabolic phenomena related to training and exercise, minimum partial eta square (η2) of 0.2 was adopted, i.e. a large effect size for differences between examined groups and consecutive examination across was expected. Other assumptions were nonsphericity correction = 0.75, number of measurements = 4, and correlation between repeated measurements = 0.5. The minimum total sample size of 22 athletes was obtained.
Body composition was assessed using dual X-ray absorptiometry (Lunar Prodigy, GE Healthcare, USA). Skeletal muscle mass was estimated using regression equations.
Graded exercise tests on a treadmill (h/p/cosmos, Germany) were conducted before 12 a.m., two hours after a standard meal. The initial speed was 8 km/h and increased every 3 min by 2 km/h until exhaustion. Respiratory parameters and heart rate were measured (ergospirometer MetaLyzer 3B, Cortex, Germany; Polar Elektro RS 400, Finland). Maximum oxygen consumption was measured.
Blood sampling. Peripheral venous catheter was placed into dorsal metacarpal vein. Blood samples were drawn at rest, during exercise (every 3 min, at each speed change), and immediately, 5, 10, 15, 20, and 30 min after exercise completion. The volume of venous blood obtained during one examination was 25 ml, i.e. 2.5 ml for each sample, up to 10 samples. Each sample was collected into plasma-separation tube containing EDTA for further plasma analysis. Samples were centrifuged at 13,000 revolution/min for 3 min at 4°C. Obtained plasma was then pipetted into 0.5 ml vials and immediately frozen in liquid nitrogen. Samples were stored in -80°C until analysis.
Forty two PFAAs were assayed: O-Phospho-L-serine, O-Phosphoethanolamine, Taurine, L-Asparagine, L-Serine, Hydroxy-L-proline, Glycine, L-Glutamine, Ethanolamine, L-Aspartic acid, L-Citrulline, Sarcosine, β-Alanine, L-Alanine, L-Threonine, L-Glutamic acid, L-Histidine, 1-Methyl-L-histidine, 3-Methyl-L-histidine, L-Homocitrulline, Argininosuccinic acid, γ-Amino-n-butyric acid, D, L-β-Aminoisobutyric acid, L-α-Amino-n-butyric acid, L- α- Aminoadipic acid, L-Anserine, L-Carnosine, L-Proline, L-Arginine, δ-Hydroxylysine, L-Ornithine, Cystathionine, L-Cystine, L-Lysine, L-Valine, L-Methionine, L-Tyrosine, L-Homocystine, L-Isoleucine, L-Leucine, L-Phenylanine, L-Tryptophan. The analysis of PFAAs was based on the LC-ESI-MS/MS technique and the aTRAQ (Sciex) reagent, characterized by high sensitivity and specificity, short analytical run time, low sample volume required to perform the analysis, and high amount of analytes being quantified in one run.
Protocol for determination of PFAAs. Plasma samples of 40 µl were transferred to Eppendorf tubes. In order to precipitate proteins present in plasma, 10 µl of 10% sulfosalicylic acid was added and the content was mixed and centrifuged (10,000 g for 2 minutes). After that, the supernatant was transferred to a new tube and mixed with 40 µl of borate buffer. An aliquot of 10 µl of the obtained solution was subsequently labeled with the aTRAQ reagent Δ8 solution (5 µl), mixed, centrifuged, and incubated at room temperature for 30 minutes. The labeling reaction was then stopped by addition of 5 µl of 1.2% hydroxylamine, mixed, and incubated at room temperature for 15 minutes. After that, 32 µl of the internal standard solution was added and the content was mixed. In the next step, the sample was evaporated in a vacuum concentrator for 15 minutes to reduce the volume of the sample to about 20 µl. The residue was then diluted with 20 µl of water, mixed, and transferred to an autosampler vial with an insert. This procedure was modified in order to measure the concentrations of PFAAs that could not be detected using the original method. For this purpose, plasma samples of higher volume were used for the sample preparation procedure. Instead of 40 μl, plasma samples of 80 μl were transferred to Eppendorf tubes and mixed with 20 μl of 10% sulfosalicylic acid. After that, 20 μl of the supernatant was transferred to a new tube and mixed with 30 μl of borate buffer. The subsequent steps of the procedure remained unchanged. The internal standard solution contained the same AAs labeled with the aTRAQ reagent Δ0. Thus, each determined PFAA had its corresponding internal standard. Norleucine and norvaline, two non-proteinogenic AAs, were used to evaluate the labeling efficiency and recovery. Their corresponding internal standards were also present in the internal standard solution.
The analyses were performed using the liquid chromatography instrument 1260 Infinity (Agilent Technologies) coupled to the 4000 QTRAP (quadrupole ion trap) mass spectrometer (Sciex). This mass spectrometer is equipped with an electrospray ionization source and three quadrupoles and allows to conduct the quantitative PFAA analysis planned within the presented project. The chromatographic separation was performed with the Sciex C18 (5 μm, 4.6 mm x 150 mm) chromatography column. The flow rate of mobile phases was maintained at 800 μl/min. The method uses the following mobile phases: water (phase A) and methanol (phase B), both with addition of 0,1 % formic acid and 0.01 % heptafluorobutyric acid. The time of analysis was 18 minutes and during that time the chromatographic separation was carried out with the following gradient elution: from 0 till 6 min - from 2% to 40% of phase B, then maintained at 40% of phase B for 4 minutes, increased to 90% of phase B till 11 min and held at that ratio phases for 1 minute, then decreased to 2% of phase B and finally maintained at 2% of phase B from 13 to 18 min. The injection volume was set at 2 μl and the separation temperature at 50 °C. The ion source settings were the following: curtain gas 20 psig; ion spray voltage 4500 V; ion source temperature 600 °C; ion source gas 1 = 60 psig, ion source gas 2 = 50 psig. The mass spectrometer operated in positive ionization mode and the following parameters were applied: entrance potential = 10 V; declustering potential = 30 V; collision cell exit potential = 5 V; collision energy = 30 eV (50 eV in case of 7 compounds); collision gas: nitrogen. The PFAAs were measured in scheduled multiple reaction monitoring (sMRM) mode. This mode ensures high specificity and sensitivity in quantitative analyses. A system suitability test (analysis of a standard mixture of AAs) was conducted before each batch of samples in order to warm up and check the inter-day performance of the whole system. Data acquisition and processing were performed using the Analyst 1.5 software (Sciex). The described LC-ESI-MS/MS method for determination of AAs is well established in the Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, the co-investigator of the project.
Total blood count was performed using the device Mythic 18 (Orphée, Swiss). Capillary blood samples from fingertip (20 μl per sample) were drawn simultaneously with venous blood pre-, during and postexercise. Blood lactate concentration was measured using C-line analyzer (EKF-Diagnostic, Germany).
Long-term effect of two different training modalities - speed-power and endurance training - on changes in plasma free amino acid (PFAA) concentration at rest, during graded exercise until exhaustion and recovery period was compared. The model cohorts were highly-trained athletes. The assumption was that structured long-lasting speed-power and endurance training cause adaptations resulting in different PFAA concentration and that the changes depend on long-term sport specialization (predominant exercise type) and training phase of the one-year cycle (contribution of high-intensity exercise based on anaerobic metabolism characterized by rapid adenosine-5'-triphosphate degradation). A larger contribution of high-intensity exercise is used by speed-power athletes and in phases of specific preparation/competition. There is a lack of research on long-term effects of physical training on changes in PFAAs. This picture is supllemented by monitoring changes in a set of 42 proteinogenic and non-proteinogenic PFAAs. Short- and long-lasting effects of training on levels and time course of PFAA concentration during exercise and recovery will be shown. The main goals were:
1. To compare the effect of the two entirely different training modalities (speed-power and endurance) on PFAA concentration.
2. To observe the effect of training load character on changes in resting, exercise and post-exercise PFAA concentration in consecutive training phases of a one-year training cycle.
3. To determine the link between PFAA concentration and exercise modality, taking into account skeletal muscle mass.
II. Background
Only 3-6% of the total energy utilized during prolonged endurance exercise is derived from oxidation of AAs. However, the proportion of energy from AA catabolism considerably increases during exercise. Although protein turnover does not contribute substantially to the energy expenditure, it may fill other important functions during exercise. AAs may delay muscle glycogen depletion.
The free AA pool amounts only 2% of the total AA amount and is stored within the plasma and intra- and extracellular spaces. This small pool accounts for a continuous exchange of AAs. Blood plasma serves as a temporary reservoir of AAs, the size of which changes in response to exercise. Differences in regular training, exercise, and daily activities result in differences in PFAA levels.
Exercise duration affects PFAA levels, however, the direction of the changes may be different for specific AAs and exercise type, intensity, and duration. In contrast, muscle AAs concentration remains relatively stable. AA metabolism during prolonged exercise has been described. Reports based on a short training periods (few weeks) in power-type athletes suggest that sprint and endurance training sessions have a distinct effect on serum AAs. However, there is a lack of studies on the differences in long-term adaptation changes in PFAAs between endurance- and sprint-trained individuals, taking into account multiple blood sampling (rest, exercise, recovery) and muscle mass.
III. Methods
Over 70 athletes aged 18-32 years - speed-power (sprinters), endurance (triathletes, distance runners), and recreationally trained - were recruited. Eventually, the data of 58 of them were considered for analysis. Athletes were examined four times during one-year training cycle: (1) general preparation phase, (2) specific preparation phase, (3) competition phase, and (4) transition phase.
The main statistical tool was one-way and two-way ANOVA with repeated measures. The required sample size was computed based on given alpha (significance) level, statistical power, and effect size. The significance level α \< 0.05 and statistical power 0.8 were assumed. Based on earlier studies that compared sprint- and endurance-trained athletes in terms of other metabolic phenomena related to training and exercise, minimum partial eta square (η2) of 0.2 was adopted, i.e. a large effect size for differences between examined groups and consecutive examination across was expected. Other assumptions were nonsphericity correction = 0.75, number of measurements = 4, and correlation between repeated measurements = 0.5. The minimum total sample size of 22 athletes was obtained.
Body composition was assessed using dual X-ray absorptiometry (Lunar Prodigy, GE Healthcare, USA). Skeletal muscle mass was estimated using regression equations.
Graded exercise tests on a treadmill (h/p/cosmos, Germany) were conducted before 12 a.m., two hours after a standard meal. The initial speed was 8 km/h and increased every 3 min by 2 km/h until exhaustion. Respiratory parameters and heart rate were measured (ergospirometer MetaLyzer 3B, Cortex, Germany; Polar Elektro RS 400, Finland). Maximum oxygen consumption was measured.
Blood sampling. Peripheral venous catheter was placed into dorsal metacarpal vein. Blood samples were drawn at rest, during exercise (every 3 min, at each speed change), and immediately, 5, 10, 15, 20, and 30 min after exercise completion. The volume of venous blood obtained during one examination was 25 ml, i.e. 2.5 ml for each sample, up to 10 samples. Each sample was collected into plasma-separation tube containing EDTA for further plasma analysis. Samples were centrifuged at 13,000 revolution/min for 3 min at 4°C. Obtained plasma was then pipetted into 0.5 ml vials and immediately frozen in liquid nitrogen. Samples were stored in -80°C until analysis.
Forty two PFAAs were assayed: O-Phospho-L-serine, O-Phosphoethanolamine, Taurine, L-Asparagine, L-Serine, Hydroxy-L-proline, Glycine, L-Glutamine, Ethanolamine, L-Aspartic acid, L-Citrulline, Sarcosine, β-Alanine, L-Alanine, L-Threonine, L-Glutamic acid, L-Histidine, 1-Methyl-L-histidine, 3-Methyl-L-histidine, L-Homocitrulline, Argininosuccinic acid, γ-Amino-n-butyric acid, D, L-β-Aminoisobutyric acid, L-α-Amino-n-butyric acid, L- α- Aminoadipic acid, L-Anserine, L-Carnosine, L-Proline, L-Arginine, δ-Hydroxylysine, L-Ornithine, Cystathionine, L-Cystine, L-Lysine, L-Valine, L-Methionine, L-Tyrosine, L-Homocystine, L-Isoleucine, L-Leucine, L-Phenylanine, L-Tryptophan. The analysis of PFAAs was based on the LC-ESI-MS/MS technique and the aTRAQ (Sciex) reagent, characterized by high sensitivity and specificity, short analytical run time, low sample volume required to perform the analysis, and high amount of analytes being quantified in one run.
Protocol for determination of PFAAs. Plasma samples of 40 µl were transferred to Eppendorf tubes. In order to precipitate proteins present in plasma, 10 µl of 10% sulfosalicylic acid was added and the content was mixed and centrifuged (10,000 g for 2 minutes). After that, the supernatant was transferred to a new tube and mixed with 40 µl of borate buffer. An aliquot of 10 µl of the obtained solution was subsequently labeled with the aTRAQ reagent Δ8 solution (5 µl), mixed, centrifuged, and incubated at room temperature for 30 minutes. The labeling reaction was then stopped by addition of 5 µl of 1.2% hydroxylamine, mixed, and incubated at room temperature for 15 minutes. After that, 32 µl of the internal standard solution was added and the content was mixed. In the next step, the sample was evaporated in a vacuum concentrator for 15 minutes to reduce the volume of the sample to about 20 µl. The residue was then diluted with 20 µl of water, mixed, and transferred to an autosampler vial with an insert. This procedure was modified in order to measure the concentrations of PFAAs that could not be detected using the original method. For this purpose, plasma samples of higher volume were used for the sample preparation procedure. Instead of 40 μl, plasma samples of 80 μl were transferred to Eppendorf tubes and mixed with 20 μl of 10% sulfosalicylic acid. After that, 20 μl of the supernatant was transferred to a new tube and mixed with 30 μl of borate buffer. The subsequent steps of the procedure remained unchanged. The internal standard solution contained the same AAs labeled with the aTRAQ reagent Δ0. Thus, each determined PFAA had its corresponding internal standard. Norleucine and norvaline, two non-proteinogenic AAs, were used to evaluate the labeling efficiency and recovery. Their corresponding internal standards were also present in the internal standard solution.
The analyses were performed using the liquid chromatography instrument 1260 Infinity (Agilent Technologies) coupled to the 4000 QTRAP (quadrupole ion trap) mass spectrometer (Sciex). This mass spectrometer is equipped with an electrospray ionization source and three quadrupoles and allows to conduct the quantitative PFAA analysis planned within the presented project. The chromatographic separation was performed with the Sciex C18 (5 μm, 4.6 mm x 150 mm) chromatography column. The flow rate of mobile phases was maintained at 800 μl/min. The method uses the following mobile phases: water (phase A) and methanol (phase B), both with addition of 0,1 % formic acid and 0.01 % heptafluorobutyric acid. The time of analysis was 18 minutes and during that time the chromatographic separation was carried out with the following gradient elution: from 0 till 6 min - from 2% to 40% of phase B, then maintained at 40% of phase B for 4 minutes, increased to 90% of phase B till 11 min and held at that ratio phases for 1 minute, then decreased to 2% of phase B and finally maintained at 2% of phase B from 13 to 18 min. The injection volume was set at 2 μl and the separation temperature at 50 °C. The ion source settings were the following: curtain gas 20 psig; ion spray voltage 4500 V; ion source temperature 600 °C; ion source gas 1 = 60 psig, ion source gas 2 = 50 psig. The mass spectrometer operated in positive ionization mode and the following parameters were applied: entrance potential = 10 V; declustering potential = 30 V; collision cell exit potential = 5 V; collision energy = 30 eV (50 eV in case of 7 compounds); collision gas: nitrogen. The PFAAs were measured in scheduled multiple reaction monitoring (sMRM) mode. This mode ensures high specificity and sensitivity in quantitative analyses. A system suitability test (analysis of a standard mixture of AAs) was conducted before each batch of samples in order to warm up and check the inter-day performance of the whole system. Data acquisition and processing were performed using the Analyst 1.5 software (Sciex). The described LC-ESI-MS/MS method for determination of AAs is well established in the Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, the co-investigator of the project.
Total blood count was performed using the device Mythic 18 (Orphée, Swiss). Capillary blood samples from fingertip (20 μl per sample) were drawn simultaneously with venous blood pre-, during and postexercise. Blood lactate concentration was measured using C-line analyzer (EKF-Diagnostic, Germany).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Healthy Athletes Aged 18-35 Years
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sprint-Trained Athletes
Highly trained track sprinters at the national or international level aged 18-35 years with sport experience 5-10 years; structured periodized training
Sprint training
Intervention Type
BEHAVIORAL
One-year cycle including specific sprint-oriented athletic training
Endurance-Trained Athletes
Highly trained long-distance runners and triathletes at the national or international level aged 18-35 years with sport experience 5-10 years; structured periodized training
Endurance training
Intervention Type
BEHAVIORAL
One-year cycle including specific endurance-oriented athletic training
Amateur/Recreational Athletes (Controls)
Individuals participating in amateur non-professional sport aged 18-35 years with activity experience 5-10 years; unstructured non-periodized training
Recreational Training
Intervention Type
BEHAVIORAL
One year of nonspecific recreational training
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sprint training
One-year cycle including specific sprint-oriented athletic training
Intervention Type
BEHAVIORAL
Endurance training
One-year cycle including specific endurance-oriented athletic training
Intervention Type
BEHAVIORAL
Recreational Training
One year of nonspecific recreational training
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* highly trained sprint- and endurance-trained athletes
* national or international performance level
* current participation in training programs organized by professional sports clubs or national team (licence) for at least 5 years
* current medical eligibility for competitive sport
* regular recreational activity for at least 5 years (preferred endurance disciplines)
* participation in amateur competition
* good health status
* non-smoking
* national or international performance level
* current participation in training programs organized by professional sports clubs or national team (licence) for at least 5 years
* current medical eligibility for competitive sport
* regular recreational activity for at least 5 years (preferred endurance disciplines)
* participation in amateur competition
* good health status
* non-smoking
Exclusion Criteria
* untrained individuals
* athletes that do not meet the above criteria for participation in professional sport
* injured athletes or those who are not able or willing to participate for other reasons
* inactive/sedentary individuals
* medical contraindications to high-intensity exercise and testing
* injured individuals or those who are not able or willing to participate for other reasons
* current smokers or heavy past smokers
* athletes that do not meet the above criteria for participation in professional sport
* injured athletes or those who are not able or willing to participate for other reasons
* inactive/sedentary individuals
* medical contraindications to high-intensity exercise and testing
* injured individuals or those who are not able or willing to participate for other reasons
* current smokers or heavy past smokers
Minimum Eligible Age
18 Years
Maximum Eligible Age
35 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poznan University of Medical Sciences
OTHER
Sponsor Role
collaborator
National Science Centre, Poland
OTHER_GOV
Sponsor Role
collaborator
Poznan University of Physical Education
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Krzysztof Kusy
Associated Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Krzysztof Kusy, PhD
Role: PRINCIPAL_INVESTIGATOR
Poznan University of Physical Education
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Poznan University of Physical Education
Poznan, Wielkoolska, Poland
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Poland
References
Explore related publications, articles, or registry entries linked to this study.
Matysiak J, Derezinski P, Klupczynska A, Matysiak J, Kaczmarek E, Kokot ZJ. Effects of a honeybee sting on the serum free amino acid profile in humans. PLoS One. 2014 Jul 29;9(7):e103533. doi: 10.1371/journal.pone.0103533. eCollection 2014.
Reference Type
BACKGROUND
Newsholme EA, Leech TR. Functional biochemistry in health and disease. Wiley-Blackwell, Chichester 2010.
Reference Type
BACKGROUND
Pitkanen H, Mero A, Oja SS, Komi PV, Pontinen PJ, Saransaari P, Takala T. Serum amino acid responses to three different exercise sessions in male power athletes. J Sports Med Phys Fitness. 2002 Dec;42(4):472-80.
Reference Type
BACKGROUND
Pitkanen H, Mero A, Oja SS, Komi PV, Rusko H, Nummela A, Saransaari P, Takala T. Effects of training on the exercise-induced changes in serum amino acids and hormones. J Strength Cond Res. 2002 Aug;16(3):390-8.
Reference Type
BACKGROUND
Rennie MJ, Edwards RH, Krywawych S, Davies CT, Halliday D, Waterlow JC, Millward DJ. Effect of exercise on protein turnover in man. Clin Sci (Lond). 1981 Nov;61(5):627-39. doi: 10.1042/cs0610627.
Reference Type
BACKGROUND
Tarnopolsky M. Protein requirements for endurance athletes. Nutrition. 2004 Jul-Aug;20(7-8):662-8. doi: 10.1016/j.nut.2004.04.008.
Reference Type
BACKGROUND
Wagenmakers AJ. Muscle amino acid metabolism at rest and during exercise: role in human physiology and metabolism. Exerc Sport Sci Rev. 1998;26:287-314.
Reference Type
BACKGROUND
Ward RJ, Francaux M, Cuisinier C, Sturbois X, De Witte P. Changes in plasma taurine levels after different endurance events. Amino Acids. 1999;16(1):71-7. doi: 10.1007/BF01318886.
Reference Type
BACKGROUND
Wolfe RR, Wolfe MH, Nadel ER, Shaw JH. Isotopic determination of amino acid-urea interactions in exercise in humans. J Appl Physiol Respir Environ Exerc Physiol. 1984 Jan;56(1):221-9. doi: 10.1152/jappl.1984.56.1.221.
Reference Type
BACKGROUND
Xiao Q, Moore SC, Keadle SK, Xiang YB, Zheng W, Peters TM, Leitzmann MF, Ji BT, Sampson JN, Shu XO, Matthews CE. Objectively measured physical activity and plasma metabolomics in the Shanghai Physical Activity Study. Int J Epidemiol. 2016 Oct;45(5):1433-1444. doi: 10.1093/ije/dyw033. Epub 2016 Apr 12.
Reference Type
BACKGROUND
Zielinski J, Kusy K. Training-induced adaptation in purine metabolism in high-level sprinters vs. triathletes. J Appl Physiol (1985). 2012 Feb;112(4):542-51. doi: 10.1152/japplphysiol.01292.2011. Epub 2011 Dec 8.
Reference Type
BACKGROUND
Ahlborg G, Felig P, Hagenfeldt L, Hendler R, Wahren J. Substrate turnover during prolonged exercise in man. Splanchnic and leg metabolism of glucose, free fatty acids, and amino acids. J Clin Invest. 1974 Apr;53(4):1080-90. doi: 10.1172/JCI107645.
Reference Type
BACKGROUND
Ahlborg G, Felig P. Lactate and glucose exchange across the forearm, legs, and splanchnic bed during and after prolonged leg exercise. J Clin Invest. 1982 Jan;69(1):45-54. doi: 10.1172/jci110440.
Reference Type
BACKGROUND
Areces F, Gonzalez-Millan C, Salinero JJ, Abian-Vicen J, Lara B, Gallo-Salazar C, Ruiz-Vicente D, Del Coso J. Changes in Serum Free Amino Acids and Muscle Fatigue Experienced during a Half-Ironman Triathlon. PLoS One. 2015 Sep 15;10(9):e0138376. doi: 10.1371/journal.pone.0138376. eCollection 2015.
Reference Type
BACKGROUND
Ballard FJ, Tomas FM. 3-Methylhistidine as a measure of skeletal muscle protein breakdown in human subjects: the case for its continued use. Clin Sci (Lond). 1983 Sep;65(3):209-15. doi: 10.1042/cs0650209. No abstract available.
Reference Type
BACKGROUND
Blomstrand E, Celsing F, Newsholme EA. Changes in plasma concentrations of aromatic and branched-chain amino acids during sustained exercise in man and their possible role in fatigue. Acta Physiol Scand. 1988 May;133(1):115-21. doi: 10.1111/j.1748-1716.1988.tb08388.x.
Reference Type
BACKGROUND
Borgenvik M, Nordin M, Mikael Mattsson C, Enqvist JK, Blomstrand E, Ekblom B. Alterations in amino acid concentrations in the plasma and muscle in human subjects during 24 h of simulated adventure racing. Eur J Appl Physiol. 2012 Oct;112(10):3679-88. doi: 10.1007/s00421-012-2350-8. Epub 2012 Feb 18.
Reference Type
BACKGROUND
Castell LM, Newsholme EA. Glutamine and the effects of exhaustive exercise upon the immune response. Can J Physiol Pharmacol. 1998 May;76(5):524-32. doi: 10.1139/cjpp-76-5-524.
Reference Type
BACKGROUND
Cuisinier C, Ward RJ, Francaux M, Sturbois X, de Witte P. Changes in plasma and urinary taurine and amino acids in runners immediately and 24h after a marathon. Amino Acids. 2001;20(1):13-23. doi: 10.1007/s007260170062.
Reference Type
BACKGROUND
Decombaz J, Reinhardt P, Anantharaman K, von Glutz G, Poortmans JR. Biochemical changes in a 100 km run: free amino acids, urea, and creatinine. Eur J Appl Physiol Occup Physiol. 1979 Apr 12;41(1):61-72. doi: 10.1007/BF00424469.
Reference Type
BACKGROUND
Derezinski P, Klupczynska A, Sawicki W, Palka JA, Kokot ZJ. Amino Acid Profiles of Serum and Urine in Search for Prostate Cancer Biomarkers: a Pilot Study. Int J Med Sci. 2017 Jan 1;14(1):1-12. doi: 10.7150/ijms.15783. eCollection 2017.
Reference Type
BACKGROUND
Einspahr KJ, Tharp G. Influence of endurance training on plasma amino acid concentrations in humans at rest and after intense exercise. Int J Sports Med. 1989 Aug;10(4):233-6. doi: 10.1055/s-2007-1024908.
Reference Type
BACKGROUND
Felig P, Wahren J. Amino acid metabolism in exercising man. J Clin Invest. 1971 Dec;50(12):2703-14. doi: 10.1172/JCI106771.
Reference Type
BACKGROUND
Gibala MJ. Regulation of skeletal muscle amino acid metabolism during exercise. Int J Sport Nutr Exerc Metab. 2001 Mar;11(1):87-108. doi: 10.1123/ijsnem.11.1.87.
Reference Type
BACKGROUND
Graham TE, Turcotte LP, Kiens B, Richter EA. Training and muscle ammonia and amino acid metabolism in humans during prolonged exercise. J Appl Physiol (1985). 1995 Feb;78(2):725-35. doi: 10.1152/jappl.1995.78.2.725.
Reference Type
BACKGROUND
Hajduk J, Klupczynska A, Derezinski P, Matysiak J, Kokot P, Nowak DM, Gajecka M, Nowak-Markwitz E, Kokot ZJ. A Combined Metabolomic and Proteomic Analysis of Gestational Diabetes Mellitus. Int J Mol Sci. 2015 Dec 16;16(12):30034-45. doi: 10.3390/ijms161226133.
Reference Type
BACKGROUND
Haralambie G, Berg A. Serum urea and amino nitrogen changes with exercise duration. Eur J Appl Physiol Occup Physiol. 1976 Dec 6;36(1):39-48. doi: 10.1007/BF00421632.
Reference Type
BACKGROUND
Hargreaves MH, Snow R. Amino acids and endurance exercise. Int J Sport Nutr Exerc Metab. 2001 Mar;11(1):133-45. doi: 10.1123/ijsnem.11.1.133.
Reference Type
BACKGROUND
Hassmen P, Blomstrand E, Ekblom B, Newsholme EA. Branched-chain amino acid supplementation during 30-km competitive run: mood and cognitive performance. Nutrition. 1994 Sep-Oct;10(5):405-10.
Reference Type
BACKGROUND
Henriksson J. Effect of exercise on amino acid concentrations in skeletal muscle and plasma. J Exp Biol. 1991 Oct;160:149-65. doi: 10.1242/jeb.160.1.149.
Reference Type
BACKGROUND
Huq F, Thompson M, Ruell P. Changes in serum amino acid concentrations during prolonged endurance running. Jpn J Physiol. 1993;43(6):797-807. doi: 10.2170/jjphysiol.43.797.
Reference Type
BACKGROUND
Ishikura K, Miyakawa S, Yatabe Y, Takekoshi K and Ohmori H. Effect of taurine supplementation on blood glucose concentration during prolonged exercise. Tairyoku Kagaku (Japanese Journal of Physical Fitness and Sport Medicien). 2008; 57, 475-484. [in Japanese]
Reference Type
BACKGROUND
Kim J, Wang Z, Heymsfield SB, Baumgartner RN, Gallagher D. Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. Am J Clin Nutr. 2002 Aug;76(2):378-83. doi: 10.1093/ajcn/76.2.378.
Reference Type
BACKGROUND
Kim J, Shen W, Gallagher D, Jones A Jr, Wang Z, Wang J, Heshka S, Heymsfield SB. Total-body skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in children and adolescents. Am J Clin Nutr. 2006 Nov;84(5):1014-20. doi: 10.1093/ajcn/84.5.1014.
Reference Type
BACKGROUND
Klupczynska A, Derezinski P, Dyszkiewicz W, Pawlak K, Kasprzyk M, Kokot ZJ. Evaluation of serum amino acid profiles' utility in non-small cell lung cancer detection in Polish population. Lung Cancer. 2016 Oct;100:71-76. doi: 10.1016/j.lungcan.2016.04.008. Epub 2016 May 7.
Reference Type
BACKGROUND
Lemon PW, Mullin JP. Effect of initial muscle glycogen levels on protein catabolism during exercise. J Appl Physiol Respir Environ Exerc Physiol. 1980 Apr;48(4):624-9. doi: 10.1152/jappl.1980.48.4.624.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPUS 14 2017/27/B/NZ7/02828
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Recovery Kinetics After Different Sprint Training Protocols (STRecovery)
NCT04766411
COMPLETED
NA
Recovery Kinetics After the Use of Small Sided Games With a Small and Large Number of Players and Large Pitch Area
NCT03970707
UNKNOWN
NA
The Effect of a 2000-m Ergometer Test on Training Status Indicators and the Muscle Adaptation in Rowers
NCT06844968
COMPLETED
NA
Physiological Responses to Maximal 4-s Sprint Interval Cycling
NCT04448925
COMPLETED
NA
Predicting the Efficacy of Resistance Exercise Training for Improving Endurance Performance
NCT04637178
COMPLETED
NA
Neurotransmitter Analysis, Stress, and Energy Availability in Athletes
NCT06683625
COMPLETED
Effects of Aerobic Blood Flow Restriction
NCT06105697
COMPLETED
NA
Linear Running Periodization x Nonlinear
NCT02498873
COMPLETED
NA
Stressors and Recovery Regulation on the Super-compensation Effect
NCT06295016
RECRUITING
NA
Hormonal Balance in Stress, Fatigue, and Recovery: Dynamics of Pre-Competition Responses
NCT06917677
COMPLETED
A Physiological Profile of Recovery From Resistance, Endurance, and Mixed Exercise Types
NCT03083509
COMPLETED
NA
Pre-Exercise Mood and Physiological Responses to Maximal Effort in Elite Rowers
NCT07243613
COMPLETED
Speed Endurance Training, Muscle Damage and Performance in Soccer Players
NCT03602248
COMPLETED
NA
Changes in the Hormonal and Inflammatory Profile of Young Sprint- and Endurance-trained Athletes.
NCT06150105
COMPLETED
Blood Flow Restriction and Recovery in Soccer Players
NCT05097027
COMPLETED
NA
Using Energy Availability as a Strategy to Explore the Effects of Relative Energy Deficiency in Sport on Athletes
NCT05649267
UNKNOWN
The Effect of Recovery Training on Lower Extremity Explosive Strength in Tennis Players
NCT07306351
ENROLLING_BY_INVITATION
NA
Relative Energy Deficiency in Rowers
NCT06452758
NOT_YET_RECRUITING
Impact of Exercise on Immune System and Metabolism in Football Players
NCT06201052
COMPLETED
Acute Effects of Static Stretching in Warm-up
NCT03298789
COMPLETED
NA
Recovery Following Acute Endurance Training
NCT06043492
COMPLETED
NA
Hematological Factors and Iron Status in Aerobic Versus Anaerobic Training in Athletic Females
NCT05707455
COMPLETED
Plyometric and Eccentric Training in Improving the Strength, Stability and Ability of Women Soccer Players
NCT04255290
COMPLETED
NA
Effect of Baseline Ferritin Level on Iron Status in Male Elite Youth Rowers
NCT06878040
COMPLETED
Acute Responses to a Potentiation Warm-up Protocol in Female Football Players.
NCT06555185
COMPLETED
NA